Risankizumab Phase 3 ADVANCE and MOTIVATE Crohn's Disease Results Published

By Hipa.ai Research · January 1, 2022

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 18, 2026.

Publication of results from the Phase 3 ADVANCE and MOTIVATE induction trials for risankizumab (Skyrizi) in moderately to severely active Crohn's disease occurred on January 1, 2022. These pivotal studies evaluated risankizumab as an induction therapy for this chronic inflammatory condition. The findings were published, detailing the efficacy and safety profile of the drug.

Background

Risankizumab (Skyrizi) is an investigational therapy for Crohn's disease, a chronic inflammatory bowel disease that affects the digestive tract. The condition can cause debilitating symptoms, including abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The ADVANCE and MOTIVATE trials specifically investigated risankizumab as an induction therapy for participants with moderately to severely active forms of the disease.

Trial design

The published results are from two pivotal Phase 3 induction trials, ADVANCE and MOTIVATE. These studies were designed to evaluate the efficacy and safety of risankizumab in participants diagnosed with moderately to severely active Crohn's disease. The trials focused on the drug's role as an induction therapy, aiming to achieve clinical response and remission in patients.

What this means

The publication of the results from the Phase 3 ADVANCE and MOTIVATE trials provides important data for clinicians and researchers treating patients with moderately to severely active Crohn's disease. These findings contribute to the understanding of risankizumab's potential as an induction therapy for this challenging condition. The availability of these pivotal trial results allows for a detailed review of the drug's efficacy and safety profile in the context of Crohn's disease management.

Source

The information regarding the publication of these trial results was sourced from PubMed. The article, titled "Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials," was published on January 1, 2022. The details are available on pubmed.ncbi.nlm.nih.gov.